Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.
Yuchen GuGautier MoroyJean-Louis PaulAnne-Sophie RebillatMara DierssenRafael de la TorreCécile Cieuta-WaltiJulien DairouNathalie JanelPublished in: International journal of molecular sciences (2020)
Epigallocatechin gallate (EGCG) is an inhibitor of DYRK1A, a serine/threonine kinase considered to be a major contributor of cognitive dysfunctions in Down syndrome (DS). Two clinical trials in adult patients with DS have shown the safety and efficacy to improve cognitive phenotypes using commercial green tea extract containing EGCG (45% content). In the present study, we performed a preclinical study using FontUp®, a new nutritional supplement with a chocolate taste specifically formulated for the nutritional needs of patients with DS and enriched with a standardized amount of EGCG in young mice overexpressing Dyrk1A (TgBACDyrk1A). This preparation is differential with previous one used, because its green tea extract has been purified to up 94% EGCG of total catechins. We analyzed the in vitro effect of green tea catechins not only for EGCG, but for others residually contained in FontUp®, on DYRK1A kinase activity. Like EGCG, epicatechin gallate was a noncompetitive inhibitor against ATP, molecular docking computations confirming these results. Oral FontUp® normalized brain and plasma biomarkers deregulated in TgBACDyrk1A, without negative effect on liver and cardiac functions. We compared the bioavailability of EGCG in plasma and brain of mice and have demonstrated that EGCG had well crossed the blood-brain barrier.
Keyphrases
- molecular docking
- clinical trial
- high fat diet induced
- oxidative stress
- white matter
- randomized controlled trial
- type diabetes
- cell proliferation
- tyrosine kinase
- left ventricular
- adipose tissue
- molecular dynamics simulations
- heart failure
- metabolic syndrome
- skeletal muscle
- insulin resistance
- atrial fibrillation
- study protocol